ILB-202
Phase 1An anti-inflammatory exosome candidate that inhibits NF-κB signaling; a randomized, double-blind Phase 1 in healthy volunteers showed safety and tolerability at all doses.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has finished Phase 1 of its exosome therapy ILB-202 and is preparing GMP clinical supply and wider indications.
Roles often seen at this stageResearch & development · Clinical & PV · Manufacturing & MSAT
Develops exosome therapeutics for inflammatory diseases using its own EXPLOR exosome engineering platform.
An anti-inflammatory exosome candidate that inhibits NF-κB signaling; a randomized, double-blind Phase 1 in healthy volunteers showed safety and tolerability at all doses.
Its in-house exosome engineering platform for loading therapeutic proteins into exosomes and delivering them into cells.
Was selected for a Ministry of Health and Welfare program that supports GMP production of ILB-202 clinical drug substance.
Published ILB-202 Phase 1 results in the Journal of Extracellular Vesicles.
Gave an investor presentation at Biotech Showcase 2026 in San Francisco.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.